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Abstract
Th17 cells and their cytokines are linked to the pathogenesis of rheumatoid arthritis, a
chronic autoimmune disease characterized by joint inflammation. Th17 development is initi-
ated by combined signaling of TGF-β and IL-6 or IL-21, and can be reduced in the absence
of either IL-6 or IL-21. The aim of this study was to assess whether combinatorial IL-6/IL-21
blockade would more potently inhibit Th17 development, and be more efficacious in treating
arthritis than targeting either cytokine. We assessed in vitro Th17 differentiation efficacy in
the absence of IL-6 and/or IL-21. To investigate in vivo effects of IL-6/IL-21 blockade on
Th17 and arthritis development, antigen-induced arthritis (AIA) was induced in IL-6-/- x IL-
21R-/- mice. The therapeutic potential of this combined blocking strategy was assessed by
treating mice with collagen-induced arthritis (CIA) with anti-IL-6R antibodies and soluble (s)
IL-21R.Fc. We demonstrated that combined IL-6/IL-21 blocking synergistically reduced in
vitro Th17 differentiation. In mice with AIA, absence of IL-6 and IL-21 signaling more
strongly reduced Th17 levels and resulted in stronger suppression of arthritis than the
absence of either cytokine. Additionally, anti-IL-6/anti-IL-21 treatment of CIA mice during
the arthritis induction phase reduced disease development more potent than IL-6 or IL-21
inhibition alone, as effective as anti-TNF treatment. Collectively, these results suggest dual
IL-6/IL-21 inhibition may be a more efficacious therapeutic strategy compared to single cyto-
kine blockade to suppress arthritis development.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects up to 1% of the popu-
lation worldwide. It is characterized by chronic inflammation leading to destruction of bone
and cartilage of synovial joints [1]. Although the use of biologicals blocking a specific patho-
genic target considerably improved symptoms and prognosis of some RA patients,
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approximately 30% of the patients still fail to respond adequately to currently available treat-
ment [2–5]. Interestingly, anti-TNFα non-responders were shown to have increased levels of
T helper (Th)17 cells in their circulation [5–7], suggesting Th17 cells and Th17-derived cyto-
kines might be interesting alternative therapeutic targets in RA. Th17 cells produce various
pro-inflammatory cytokines like IL-17, IL-21, and IL-22, that have been linked to RA patho-
genesis [8–14]. Arthritis animal models have further elucidated the role of these Th17 cyto-
kines in the processes of joint inflammation and destruction of cartilage and bone [15,16].
These findings indicate that Th17 cells and their cytokines are important contributors to the
pathogenesis of chronic and destructive joint inflammation during RA.
Differentiation of Th17 cells from naïve CD4+ T cells is mediated by the enhanced expres-
sion of the transcription factor RAR-related orphan nuclear receptor γt (RORγt), originally
thought to be induced exclusively by the combined signaling of TGF-β and IL-6 [17,18]. How-
ever, later it was shown that signaling of TGF-β combined with the autocrine signaling of IL-
21 could drive Th17 differentiation as well [19–21]. Both IL-6 and IL-21 induce upregulation
of the IL-23 receptor (IL-23R) in naïve CD4+ T cells, making those cells responsive to IL-23.
IL-23 can subsequently amplify the differentiation of Th17 cells [20,22]. When either the IL-6
or IL-21 signaling pathway is absent, differentiation of naïve T cells towards Th17 cells is
reduced. However, to date it is not known whether Th17 differentiation can be further reduced
when both IL-6 and IL-21 pathways are blocked. Therefore, the purpose of this study was to
determine whether IL-6/IL-21 combinatorial pathway blockade has additional inhibitory
effects on Th17 differentiation, and more effectively reduces development of T cell-dependent
experimental arthritis. Firstly, we assessed the effects of complete IL-6/IL-21 pathway inhibi-
tion on Th17 differentiation in vitro. Secondly, we used IL-6-/- x IL-21R-/- mice to study the in
vivo effects of cytokine pathway blockade on Th17 differentiation and development of experi-
mental arthritis. Finally, we investigated the therapeutic potential of our combined blocking
strategy by treating mice with collagen-induced arthritis (CIA) with anti-IL-6R antibodies and
soluble (s)IL-21R.Fc.
Materials and methods
Mice
Wild type (WT) C57Bl6/J mice and DBA-1 mice were purchased from Janvier-Elevage (Le
Genest Saint Isle, France), and breeding pairs of the IL-21R-deficient mice on a C57Bl6/J back-
ground were provided by Pfizer. Breeding pairs of the IL-6−/− mice, back-crossed eight times
with C57Bl6/J, were a kind gift from Dr Manfred Kopf (Basel, Switzerland)[23]. Animals were
used between 10 and 12 weeks of age and were housed in filter-top cages under specific patho-
gen-free conditions. Microbiome synchronization was promoted by housing purchased WT
mice near the genetically modified mice for a period of at least one week, before initiating
experiments. A standard diet and water were provided ad libitum. Before being sacrificed by
cervical dislocation, mice were anesthetized using 2–3% isoflurane. All animal procedures
were approved by the ethics committee of the Radboud University Nijmegen (approval num-
bers 2014–045, 2010–002, and 2012–207).
In vitro stimulation of CD4+ T cells
Naïve murine T helper cells were negatively selected from spleen, isolated from IL-21R-/- or
WT C57Bl6/J mice using a mouse naïve CD4+ T Cell Isolation Kit (Miltenyi Biotec, Bergisch
Gladbach, Germany). Naïve CD4+ T cells were cultured for four days in 6-wells plates at 37˚C,
5% CO2, in RPMI-1640 medium containing 5% fetal calf serum (FCS), 50 μm β-mercaptoetha-
nol, 50 μg/ml gentamycin, and 1% pyruvate. The following Th17 stimulation cocktail was
IL-6/IL-21 targeting in experimental arthritis
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added, with or without recombinant mouse (rm)IL-6 (50 ng/ml; eBioscience, San Diego, CA,
USA): anti-CD3 (5 μg/ml; eBioscience; adsorbed to the wells over night at 4˚C), anti-CD28
(2.5 μg/ml; eBioscience), anti-IL-2 (5 μg/ml; eBioscience), TGF-β (1 ng/ml; eBioscience), IL-1β
(10 ng/ml; kind gift of Pfizer), and TNFα (10 ng/ml; eBioscience). Differentiation efficacy was
determined with flow cytometry. Supernatant cytokine levels were determined using the
Luminex multianalyte technology, in combination with Milliplex cytokine kits (Merck Milli-
pore, Darmstadt, Germany).
In vivo study protocol I: Antigen-induced arthritis (AIA) in knockout mice
AIA was induced in WT, IL-21R-/-, IL-6-/-, and IL-21R-/- x IL-6-/- mice as previously described
[24]. Inflammation of the knee joint was measured by 99mTechnetium (99mTc) pertechnetate
uptake. Joint swelling was scored as the ratio of 99mTc uptake of the arthritic right (R) and con-
trol left (L) knee joint. Joint swelling of the right knee joint was indicated as R:L ratios>1.1.
Mice were sacrificed by cervical dislocation either at day 2 or day 7 after arthritis induction,
and serum and joints were collected for further analysis. Draining lymph nodes (dLN) of mice
sacrificed two days after arthritis induction were isolated to determine Th17 levels.
In vivo study protocol II: Antibody treatment during collagen-induced
arthritis (CIA)
CIA was induced as described previously [25]. Arthritis development was macroscopically
scored on a scale of 0–2 per paw, according to changes in redness and/or swelling of the paws.
IL-6 signaling was inhibited with a single bolus intraperitoneal (i.p.) injection with 8 mg of a
rat anti-mouse IL-6 receptor antibody (MR16-1; kind gift of Chugai Pharmaceutical Co. Ltd).
IL-21 was neutralized by three i.p. injections per week with 200 μg soluble (s)IL-21R.Fc (Pfizer,
New York, NY, USA), from now on referred to as anti-IL-21 therapy [26,27]. Treatment was
initiated at the day of immunization (day 0, early treatment), or at the day of booster injection
(day 21, late treatment). Both treatments were administered as single and combination treat-
ments. The TNFα inhibitor Enbrel (200 μg; Pfizer) and rat IgG1 (200 μg; Pfizer) were injected
as positive and negative control respectively, both i.p. 3 times a week. Mice were terminally
bled at day 35 to determine serum antibody levels. Subsequently ankle joints were isolated for
X-ray and histological analysis, and draining popliteal and inguinal lymph nodes were isolated
to determine T cell levels.
Histology
Isolated joints were fixed for at least four days in 4% formaldehyde, decalcified in 5% formic
acid, dehydrated, and embedded in paraffin. Standard frontal sections of 7 μm were mounted
on SuperFrost slides (Menzel-Gla¨ser, Braunschweig, Germany), and stained with haematoxy-
lin and eosin (H&E), or Safranin O (SO). Joint arthritis severity was scored on an arbitrary
scale of 0–3, as previously described [28]. Histopathological changes were scored on three
semiserial sections of the joint, in a blindfolded manner.
Flow cytometry
Cells were stimulated four hours with phorbol myristate acetate (PMA; 50 ng/ml; Sigma-
Aldrich, Saint Louis, MO, USA), ionomycin (1 μg/ml; Sigma-Aldrich) and the Golgi-traffic
inhibitor Brefeldin (1 μl/ml; BD Biosciences, Franklin Lakes, NJ, USA). Differentiated T cells
or isolated LN cells were stained with anti-CD3-PE (BD Biosciences) and anti-CD4-APC (Bio-
legend, San Diego, CA, USA), fixed and permeabilized using BD Cytofix/Cytoperm (BD
IL-6/IL-21 targeting in experimental arthritis
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Biosciences), followed by intracellular staining with anti-IL-17-FITC (Biolegend), anti-IFNγ-
FITC (BD Biosciences), or appropriate isotype-matched control antibodies (all from BD Bio-
sciences). Cells were measured on a FACSCalibur using the CellQuest software (BD Biosci-
ences), and analyzed using FlowJo software (version 7.6.5).
Measurement of anti-mBSA and anti-CII antibodies
Levels of anti-mBSA and anti-CII antibodies were determined in serum using enzyme-linked
immunosorbent assay (ELISA). In short, 10 ng of mBSA or 100 ng of bovine type II collagen
were coated onto 96-well plates overnight. Nonspecific binding sites were blocked with 1%
BSA in PBS-Tween (0.05%) for anti-mBSA antibody detection, and with a 5% milk powder
solution for anti-CII antibody detection. Serial dilutions of mouse sera were incubated for 1
hour, before adding isotype-specific horseradish peroxidase-labeled goat anti-mouse Ig
(1:1000). After incubation of another hour, 5-aminosalicyclic acid was added as a substrate,
absorbance was subsequently measured at 450 nm.
Statistics
To determine the level of statistical significance between means of experimental groups, the
Kruskal-Wallis with a Dunns post-test, or a one-way ANOVA with a Bonferroni post-test was
applied as indicated, using GraphPad Prism version 5. P values less than 0.05 are considered
significant. Results are expressed as Tukey box plots.
Results
Combined blocking of IL-6 and IL-21 synergistically inhibits in vitro Th17
differentiation
To investigate the exchangeability of IL-6 and IL-21 and potential additive or synergistic effects
of these cytokines during Th17 differentiation, we first determined the differentiation efficacy
of naïve T cells towards Th17 cells in the presence of both IL-6 and endogenous IL-21. After
culturing, 86% of CD4+ cells were positive for IL-17 (Fig 1A and 1B), and produced high levels
of IL-17 (Fig 1C). Subsequently, we determined Th17 differentiation efficacy in the absence of
either IL-6 or IL-21 signaling. Without IL-6, naïve T cells reached only 46% of Th17 develop-
ment upon stimulation, while Th17 differentiation efficacy of naïve IL-21R-/- T cells was simi-
lar to that observed after stimulation of WT cells (Fig 1A and 1B). Interestingly, when both IL-
6 and IL-21 signaling pathways were absent, only 17% of CD4+ cells differentiated into Th17
cells after culturing (Fig 1A and 1B), and IL-17 secretion was reduced by 50% (Fig 1C). High
endogenous IL-21 levels were detected in supernatants of cultures with IL-6 (Fig 1D), poten-
tially contributing to Th17 development in an autocrine fashion [19–21]. Finally, secretion of
IL-22 in supernatant of those cultures was confirmed (Fig 1E). This shows that by blocking IL-
6 and IL-21 signaling pathways in vitro, Th17 differentiation is dramatically reduced, thereby
providing excellent rationale for further in vivo studies.
Th17 differentiation and arthritis severity are potently reduced by
combinatorial blockade of IL-6 and IL-21 signaling pathways
We next investigated the in vivo effects of IL-6 and IL-21 pathway blockade on Th17 differenti-
ation and the development of experimental arthritis. The T cell-driven AIA model was
induced in WT, IL-6-/-, IL-21R-/-, and IL-6-/- x IL-21R-/- mice, and the number of Th17 cells in
draining LNs was assessed two days after arthritis onset. Expression of various T (CD3, CD4,
CD8) and B (CD45R, CD19, CD22) cell markers was unaffected in spleens of IL-6-/- x IL-
IL-6/IL-21 targeting in experimental arthritis
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21R-/- mice as compared to WT, indicating normal lymphocyte development (data not
shown). Among total measured cell population of WT mice, 0.3% was CD4+IL-17+ (Fig 2A).
In line with our in vitro data, Th17 levels were reduced in mice lacking IL-6 signaling, and in
mice in which both IL-6 and IL-21R were absent. Remarkably, in contrast to our in vitro data
(Fig 1), IL-21R-/- mice also showed significantly reduced Th17 numbers in vivo (Fig 2A). In
addition to its importance in T cell development, IL-21 has been implicated in B cell develop-
ment and antibody production [29,30], processes relevant to RA and important in this experi-
mental arthritis model as well. Hence, we were interested in determining the effect of a lack in
IL-6 but especially in IL-21 on antibody production in AIA. Unexpectedly, we did not observe
any effect on antibody titers in mice deficient only for the IL-21R (Fig 2B). However, mice
lacking both IL-6 and IL-21R expression showed reduced antibody production as compared to
Fig 1. Highly reduced Th17 differentiation in the absence of both IL-6 and IL-21 signaling. WT and IL-
21R-/- naïve T cells were stimulated for four days with a differentiation cocktail either with or without IL-6 as
described in Methods. Representative flow cytometry dot plots reflecting the IL-17+ fraction of the CD4
+ population. Gates were set at a maximum of 0.3% IL-17-positive cells in the ‘fluorescence minus one’
control per condition, without addition of IL-17A antibodies (A). Summary of the relative proportion of IL-17
+ cells within the CD4+ population (B). Culture supernatant levels of IL-17 (C), IL-21 (D), and IL-22 (E). 6–10
mice/group; *p<0.05, **p<0.01, ***p<0.001 versus WT + IL-6; ###p<0.001 versus WT—IL-6; ^p<0.05,
^^^p<0.001 versus IL-21R-/- + IL-6; A—Kruskal-Wallis, B-D—One-way ANOVA.
doi:10.1371/journal.pone.0171757.g001
IL-6/IL-21 targeting in experimental arthritis
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WT controls (Fig 2B), suggesting that combined deficiency of IL-6 and IL-21 can significantly
suppress the development of disease-relevant antibodies.
In line with lowered Th17 levels, reduced joint swelling was measured in the absence of IL-
6 or IL-21R, as compared to WT controls (Fig 3A–3C). Interestingly, joint swelling was
reduced more potently in IL-6-/- x IL-21R-/- mice compared to mice lacking either IL-6 or IL-
21R expression early in disease development (Fig 3A and 3B). Even though joint swelling of
WT mice started to decline four days after arthritis induction, joint swelling was still signifi-
cantly lower in all knock out groups (Fig 3C). Importantly, when assessing histologically
scored inflammation, cartilage proteoglycan (PG) depletion, and bone erosion at this time
point, we observed significantly reduced damage in IL-6-/-, IL-21R-/-, and IL-6-/- x IL-21R-/-
mice as compared to the WT controls for all parameters (Fig 3D).
Overall, this study confirmed the importance of IL-6 and IL-21 during Th17 development
in vivo, and showed higher potency of blocking both cytokine pathways above blocking either
one in reducing the severity of arthritis.
Combination therapy with anti-IL-6R antibodies and sIL-21R.Fc more
potently suppresses disease development than targeting either cytokine
during the induction phase of experimental arthritis
To determine the therapeutic potential of combined IL-6/IL-21 signaling pathway blockade
during experimental arthritis, mice with CIA were treated with anti-IL-6R antibodies and/or
Fig 2. IL-6 and IL-21 play an important role during in vivo Th17 differentiation and antibody
production. AIA was induced in WT, IL-6-/-, IL-21R-/-, and IL-6-/- x IL-21R-/- mice. Draining lymph node CD4
+IL-17+ cell fraction two days after arthritis induction as measured using flow cytometry (A; n = 10/group).
Serum IgG1, IgG2b, and total IgG levels as measured by ELISA (B; n = 5/group). *p<0.05, **p<0.01,
***p<0.001 versus WT; ##p<0.01 versus IL-6-/-; ^^^p<0.001 versus IL-21R-/-; A—One-way ANOVA, B—
Kruskal-Wallis.
doi:10.1371/journal.pone.0171757.g002
IL-6/IL-21 targeting in experimental arthritis
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sIL-21R.Fc starting either from the day of immunization (day 0, early treatment), or from the
day of the booster injection (day 21, late treatment).
Surprisingly, mice receiving early anti-IL-6R antibody and/or anti-IL-21 treatment, only
showed a minor trend towards lower Th17 levels in their LNs as compared to isotype control
mice (Fig 4A). This trend in Th17 reduction was not present when treatment was initiated
later in the disease process, i.e. at the day of booster injection. Th1 levels were largely unaf-
fected, except for a minor trend towards an increase in mice receiving early combination treat-
ment (Fig 4B). In contrast to observations in our AIA study using knockout mice (Fig 2B), we
did not observe any changes in antibody profile when using this anti-IL-6/anti-IL-21 treatment
strategy in mice with CIA (Fig 4C).
Even though the effect of cytokine neutralization on Th17 levels was minor, we observed
potent clinical effects of this treatment strategy. Mice receiving early αIL-6R antibody treat-
ment showed potently reduced disease incidence compared to isotype-treated mice, with only
60% of these mice having arthritis at day 35 (Fig 5A). Interestingly, arthritis incidence was fur-
ther reduced when mice were treated with the anti-IL-6R/anti-IL-21 combination therapy,
resulting in only 40% of mice developing arthritis. This greatly reduced disease incidence
shows the potential of the early IL-6/IL-21 combination strategy over single cytokine inhibi-
tion in blocking arthritis development, with comparable efficacy as the positive control group
receiving TNFα inhibitors. In contrast to early anti-IL-6R therapy, late treatment with anti-IL-
6R antibodies could not inhibit arthritis; all mice developed arthritis already around day 23
(Fig 6A). Remarkably, mice treated with the late anti-IL-6R/anti-IL-21 combination therapy
Fig 3. Antigen-induced arthritis severity is potently reduced by combinatorial blockade of IL-6 and IL-21 signaling pathways.
Joint swelling of WT, IL-6-/-, IL-21R-/-, and IL-6-/- x IL-21R-/- mice at day 1 (A), day 2 (B), and day 4 (C) after arthritis induction, depicted as
ratio between right and left knee joint, measured by 99mTechnetium pertechnetate uptake in the joint (n = 6/group). Histologically scored
inflammation, bone erosion (both H&E staining, scale bar 500 μM), and cartilage proteoglycan depletion (SafO staining, scale bar 200 μM)
(D; n = 10/group). *p<0.05, **p<0.01, ***p<0.001 versus WT; #p<0.05, ###p<0.001 versus IL-6-/-; ^p<0.05 versus IL-21R-/-; A+B One-
way ANOVA, C+D Kruskal-Wallis.
doi:10.1371/journal.pone.0171757.g003
IL-6/IL-21 targeting in experimental arthritis
PLOS ONE | DOI:10.1371/journal.pone.0171757 February 3, 2017 7 / 16
show a clear protective effect on arthritis incidence; only 60% of those mice developed arthritis
before the end of the study (day 30). Unfortunately, none of the late experimental treatments
had an effect on arthritis severity, as joint swelling (Fig 6B), radiological bone damage (Fig
6C), and histological damage (Fig 6D), were all comparable to levels measured in the isotype
control group. In mice treated from the day of immunization with anti-IL-6 and anti-IL-21
treatment on the other hand, clinical arthritis severity based on swelling and redness of the
four paws was greatly reduced in comparison with the isotype control group (Fig 5B). Unex-
pectedly, we found reduced radiological scored bone damage only to be significant in early
anti-IL-6R antibody receiving mice, with no additional value of blocking IL-21 (Fig 5C). Inter-
estingly, histological damage was reduced more potent in mice receiving anti-IL-6/IL-21 com-
binatorial treatment than in mice receiving single anti-IL-6 or anti-IL-21 treatment (Fig 5D),
altogether suggesting higher efficacy of this combination treatment strategy over single cyto-
kine blockade during the induction phase of the disease.
Discussion
IL-6 and IL-21 are important mediators in the differentiation of Th17 cells [17–19]. The
redundancy and possible additive or synergistic effects of the IL-6 and IL-21 pathways, as well
as the therapeutic potential of combined pathway blockade in Th17-driven autoimmunity
remain unclear. This study on the role of IL-6 and IL-21 during Th17 differentiation and the
development of experimental arthritis revealed synergistic effects of IL-6 and IL-21 signaling
pathways in driving Th17 differentiation in vitro, and indicated that the IL-6/IL-21 combina-
tion blocking strategy may be a highly effective way of treating patients with early rheumatoid
arthritis.
Fig 4. Effect of anti-IL-6 and/or anti-IL-21 treatment on Th17, Th1, and antibody development in CIA
mice. Th17 (A) and Th1 (B) levels in draining lymph nodes as measured using flow cytometry, and anti-CII
antibody level in serum (C) as measured by ELISA of mice with CIA receiving anti-IL-6 and/or anti-IL-21
treatment. n = 5/group; **p<0.01 versus Rat IgG1; A+C—Kruskal-Wallis, B—One-way ANOVA.
doi:10.1371/journal.pone.0171757.g004
IL-6/IL-21 targeting in experimental arthritis
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In accordance with previously reported data on in vitro Th17-differentiation [17,18], we
showed significantly lower levels of IL-17-producing CD4+ cells when differentiating naïve T
cells in the absence of IL-6. However, we observed no reduction in Th17 differentiation when
solely IL-21 signaling was blocked, indicating that IL-21 is not a critical factor during Th17 dif-
ferentiation in vitro. Data from earlier studies on the role of IL-21 in in vitro Th17 differentia-
tion are ambivalent. IL-21 is suggested to be essential for differentiation of Th17 cells [20],
whereas others claim IL-21 is capable of, but not necessary for, driving Th17 development
[31,32], the latter being in line with the current study. Although we cannot fully explain this
discrepancy, the reason might lie within the concentrations of the various cytokines and anti-
bodies used to drive T cell differentiation, or within the mouse strain used to isolate naïve T
cells. Interestingly, when both IL-6 and IL-21 pathways were inactive, differentiation of naïve
Fig 5. Arthritis incidence and severity of mice receiving anti-IL-6 and/or anti-IL-21 treatment during the induction phase of the
disease. Collagen-induced arthritis was initiated in DBA-1 mice, subsequently treated with anti-IL-6R antibodies and/or sIL-21R.Fc from the
day of the immunization injection (d = 0; n = 5/group). Arthritis incidence (A) and severity (B) based on macroscopic scoring. Bone damage
as measured using the Faxitron depicted as radiological damage (C). Histologically scored inflammation, bone erosion (both H&E staining,
scale bar 500 μM), and cartilage proteoglycan depletion (SafO staining, scale bar 200 μM) (D). *p<0.05, **p<0.01 versus Rat IgG1; One-
way ANOVA.
doi:10.1371/journal.pone.0171757.g005
IL-6/IL-21 targeting in experimental arthritis
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T cells towards Th17 cells was almost completely blocked, clearly showing the synergy between
the two pathways in driving Th17 differentiation in vitro.
Accordingly, significantly reduced Th17 levels were present in draining lymph nodes of
arthritic mice in which the IL-6 pathway was blocked, two days after induction of the AIA
model. Moreover, blocking both IL-6 and IL-21 pathways resulted in almost undetectable
Th17 levels, showing the importance of these two cytokines in driving Th17 differentiation
in vivo. As IL-6 and IL-21 are both important in inducing IL-23 receptor expression in naïve
CD4+ T cells, this combined blockade might reduce IL-23R expression levels, and thereby IL-
23 signaling, to a minimum, possibly contributing to the major reduction in Th17 levels
[20,22], In line with previously published data, arthritis severity was significantly reduced in
IL-6-/- mice as compared to WT controls, two days after arthritis induction [33]. Earlier work
Fig 6. Arthritis incidence and severity of mice receiving anti-IL-6 and/or anti-IL-21 treatment late in disease development.
Collagen induced arthritis was initiated in DBA-1 mice, subsequently treated with anti-IL-6R antibodies and/or sIL-21R.Fc from the day of
booster injection (d = 21; n = 5/group). Arthritis incidence (A) and severity (B) based on macroscopic scoring. Bone damage as measured
using the Faxitron depicted as radiological damage (C). Histologically scored inflammation, bone erosion (both H&E staining, scale bar
500 μM), and cartilage proteoglycan depletion (SafO staining, scale bar 200 μM) (D). *p<0.05 versus Rat IgG1; One-way ANOVA.
doi:10.1371/journal.pone.0171757.g006
IL-6/IL-21 targeting in experimental arthritis
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of our group showed reduced arthritis severity in IL-21R-/- mice as compared to WT controls
[24], the present study confirms these data. Additionally, both studies show reduced IL-17 pro-
duction by CD4+ cells of mice lacking expression of the IL-21 receptor. Interestingly, as
opposed to this T cell effect, previous studies showed the reducing effect of IL-21 blockade on
arthritis development could be attributed to a defect in B cell development rather than in T cell
development in the K/BxN and collagen-induced arthritis (CIA) murine arthritis models
[34,35]. In contrast to our study, Th17 responses were unaffected in IL-21R-/- mice with CIA
[35], as well as in IL-21R-/- mice with experimental autoimmune encephalitis (EAE) and myo-
carditis (EAM) [32]. The exact reason for this discrepancy in mechanism of disease reduction
remains unclear, but might reflect the pleiotropic character of IL-21, with the genetic and
inflammatory context influencing the functioning of the cytokine. Regardless of the mecha-
nism of action, a block in IL-21 reduced experimental arthritis development in the majority of
reported studies, including the present study. Of high interest, our double blocking strategy
was most effective in reducing arthritis severity, which is in concordance with Th17 levels of
those animals. These data hint towards therapeutic potential of using a combined IL-6/IL-
21-blocking treatment strategy.
Indeed, when treating mice with both anti-IL-6R antibodies and sIL-21R.Fc either during
the induction phase of arthritis (day 0) or in a later stage of the disease (day 21), arthritis inci-
dence levels could potently be reduced, confirming the therapeutic potency of this strategy in a
RA mouse model. Also in comparison with mice treated solely with anti-IL-6R antibodies, a
compound currently used to effectively treat RA patients [36] and known as Tocilizumab (JW
Pharmaceutical, Seoul, South Korea), the combination treatment proved to be much more
potent in preventing arthritis development. This holds true when treatment was initiated early
during arthritis development, but especially when first therapeutic injections were adminis-
tered in a later stage of the disease, where the anti-IL-6R antibodies could not prevent disease
onset. Tocilizumab is a humanized anti-IL-6R monoclonal antibody that has been tested in the
clinic both as a monotherapy, as well as in combination with disease-modifying anti-rheumatic
drugs (DMARDS), the first-line treatment for RA patients. Tocilizumab monotherapy potently
inhibited structural joint damage, and led to increased percentages of patients achieving
ACR20, 50 and 70 responses. Additionally, the number of patients achieving remission as
defined by a Disease Activity Score in 28 Joints (DAS28) lower than 2.6, was increased in Toci-
lizumab-treated patients [37–40]. Samson et al. suggest that the successes of Tocilizumab may
be attributed to a correction of the imbalance between the pathogenic Th17 cells and the pro-
tective regulatory T (Treg) cells that is found in part of the RA patients [41]. They showed
decreased Th17 levels in peripheral blood of RA patients after Tocilizumab treatment, whereas
Treg numbers were increased. As arthritis development in mice was more effectively reduced
by our combination treatment than by the anti-IL-6R antibodies, a similar response may be
expected when treating patients with Th17-driven joint pathologies, suggesting the potential
of adding an anti-IL-21 treatment to the currently used Tocilizumab monotherapies.
In addition to reduced incidence after anti-IL-6R/anti-IL-21 treatment, disease severity of
arthritic mice receiving early combination therapy was reduced. Interestingly, neither anti-IL-
6R antibodies, nor anti-IL-21 therapy as single treatments could reduce arthritis severity in the
severe and progressive collagen-induced arthritis model. A partial difference in the outcome of
anti-IL-6R antibody treatment is present compared to earlier studies [27,42], which may be
due to different study design. In line with our data, no protective effect was observed when this
treatment was initiated later in disease development. Radiological bone damage of the knee
and ankle joints was significantly reduced only in mice receiving early treatment with anti-IL-
6R antibodies alone, a trend towards reduction was observed when combined with anti-IL-21
therapy, to levels comparable to that of anti-TNFα treated mice. Histological damage was only
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reduced by the combination treatment, again to levels comparable to those observed in mice
treated with TNFα inhibitors.
Interestingly, a clear trend towards reduced Th17 levels in draining lymph nodes of mice
receiving either early single or combination treatment was present, despite the late time point
of analysis (day 35). In contrast, no reduced Th17 levels were observed when treatment was
initiated later in disease development. Data of mice treated with anti-IL-6R antibodies initiated
at both time points confirm previously published data [42]. Although our in vitro data demon-
strated synergy between IL-6 and IL-21 in Th17 differentiation, this was not clearly reflected
by Th17 levels in draining lymph nodes of arthritic mice during our in vivo studies. Determi-
nation of T cell levels in inflamed synovium may provide more information on local differ-
ences in T cell subsets.
Over the past few years, clinical trials have been performed testing various IL-17-targeting
agents for a number of autoimmune diseases, amongst others Rheumatoid Arthritis. In RA
patients who failed to respond to synthetic and/or biologic DMARDs, both ixekizumab and
secukinumab, two agents targeting the IL-17A ligand, induced small but clinically relevant
responses. Reported safety profiles were similar to that of other biological agents [43–48]. In
contrast, no clinical response was observed when treating RA patients with the anti-IL-
17-receptor antibody brodalumab [49,50], a clear explanation for the differences in efficacy of
ligand versus receptor targeting is lacking. Even though these studies indicate targeted inhibi-
tion of the IL-17A ligand may have therapeutic value in the treatment of RA, pharmaceutical
companies appear to shift the application of their anti-IL-17 therapies to other rheumatic dis-
eases like psoriatic arthritis [51,52] and ankylosing spondylitis [53]. Most likely because
obtained clinical effects of IL-17 blocking strategies in RA were below expectation, especially
when comparing with the impressive therapy responses observed in patients suffering from
plaque psoriasis [54].
As IL-17 and other Th17-derived cytokines are important contributors to RA pathology
[8–16], identifying other ways to target this pathway remains a high priority. With this study
we demonstrated that full inhibition of both IL-6 and IL-21 effectively abrogates Th17 differ-
entiation, and that, despite the minor effect on Th17 development, a combination therapy neu-
tralizing both cytokine pathways is more effective in treating early T cell-driven experimental
arthritis than targeting either cytokine. This indicates that anti-IL-6/IL-21 combination ther-
apy might be an interesting new strategy to treat early RA patients or to sustain RA remission.
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